CGEM · Cullinan Therapeutics Inc.
AI read · Good for CGEM
The AI's read
Cullinan's REZILIENT3 Phase 3 interim hit its primary PFS endpoint and the company says safety was manageable. That moves zipalertinib from a second-line hopeful to a real first-line contender. Price action is muted so far, up ~0.5% while RSI sits at 32, so the market hasn't fully priced a big rerating. NDA acceptance and a DSMB unblinding recommendation add follow-on catalysts. We lean bullish here: clear efficacy read, accepted NDA, and cash runway into 2029 reduce binary risk and give upside optionality. Conviction 84% because the clinical win is concrete and directly relevant to approval path.